证券代码：600165 股票简称：宁科生物 公告编号：临 2023-047 宁夏中科生物科技股份有限公司 重大诉讼公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 案件所处的诉讼阶段：立案受理，尚未开庭。 ● 是否会对上市公司损益产生负面影响：鉴于案件尚未审理，目前无法准 确判断对宁夏中科生物科技股份有限公司（以下简称：公司）本期利润或期后 利润的影响，最终影响以法院审理结果为准。 ● 法院出具的财产保全裁定书，仅为相关方采取的财产保全措施，公司目 前生产经营情况正常。 一、本次重大诉讼的基本情况 因股权转让合同纠纷，公司控股子公司宁夏中科生物新材料有限公司（以下 简称：中科新材）股东宁夏产业引导基金管理中心（有限公司）（以下简称：产 业基金）作为原告向宁夏回族自治区银川市中级人民法院（以下简称：银川市中 院）提交了《民事起诉状》，对被告上海中能企业发展(集团)有限公司（以下简 称：上海中能）、公司、中科新材提起诉讼。 二、本次重大诉讼的案件当事人、诉讼请求、事实及理由、案件进展情况 （一）案件当事人 ...

宁夏中科生物科技股份有限公司（以下简称：公司）于 2023 年 8 月 24 日收到 公司控股股东上海中能企业发展（集团）有限公司通知，公司实际控制人虞建明先 生曾于 2020 年 7 月因涉及操纵证券市场事项，为配合调查被有权机关采取强制措施， 上海市人民检察院第一分院于 2021 年 3 月 26 日受理该案件，涉及主体为上海中能 企业发展（集团）有限公司、虞建明先生以及其他 6 名自然人，2023 年 3 月 9 日上 海市人民检察院第一分院向虞建明先生出具沪检一分刑不诉【2023】12 号文书："经 本院审查并经二次退回补充侦查，本院仍然认为上海市公安局认定的犯罪事实不清、 证据不足，不符合起诉条件，依照《中华人民共和国刑事诉讼法》第一百七十五条 第四款的规定，决定对虞建明不起诉。"目前上述案件正在审理中，公司将持续关注 上述事项进展情况，严格按照有关法律、法规的规定履行信息披露义务。 公司目前生产经营情况正常，各项工作有序开展。公司指定信息披露媒体为《上 海 证 券 报 》、《 证 券 时 报 》， 指 定 信 息 披 露 网 站 为 上 海 证 券 交 易 所 网 站 （www.sse.com.c ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥101.99 million, a decrease of 78.54% compared to ¥475.30 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2023 was a loss of approximately ¥136.77 million, compared to a profit of ¥8.91 million in the same period last year, representing a decrease of 1,635.28%[18]. - The net cash flow from operating activities for the first half of 2023 was a negative ¥25.31 million, a decline of 361.39% compared to ¥9.68 million in the same period last year[19]. - The basic earnings per share for the first half of 2023 was -¥0.200, compared to ¥0.013 in the same period last year, a decrease of 1,638.46%[20]. - The weighted average return on net assets for the first half of 2023 was -24.383%, a decrease of 25.539 percentage points compared to 1.156% in the same period last year[20]. - The company reported a net loss of ¥154,054,023.08 for the first half of 2023, compared to a net profit of ¥7,241,442.69 in the first half of 2022, indicating a substantial decline in profitability[104]. - The total comprehensive loss for the first half of 2023 was ¥154,033,669.22, compared to a comprehensive income of ¥7,475,957.93 in the same period of 2022[104]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥3.15 billion, a decrease of 3.96% from ¥3.28 billion at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥492.56 million, down 21.73% from ¥629.31 million at the end of the previous year[19]. - Cash and cash equivalents decreased by 76.21% to ¥21,288,694.26, primarily due to payment of goods[41]. - Accounts receivable financing decreased by 40.26% to ¥1,389,724.25, mainly due to payments made by the subsidiary[41]. - Other current assets decreased by 83.31% to ¥355,307.82, attributed to VAT refund received by the subsidiary[41]. - Total liabilities increased from CNY 2,384,616,750.65 to CNY 2,408,713,236.66, an increase of about 1.01%[96]. - Current liabilities rose from CNY 1,566,516,438.06 to CNY 1,638,307,854.67, an increase of about 4.57%[96]. Operational Insights - The company aims to enhance its profitability by continuously expanding its market share and aligning with market demand[28]. - The company employs a mixed sales model combining direct sales, distribution, and consignment to enhance market penetration[28]. - The procurement process involves selecting multiple suppliers to ensure cost control and stable raw material supply[28]. - The company has detailed the potential risks in the "Management Discussion and Analysis" section of the report[4]. - The company has established a support plan with the local government to help Zhongke New Materials recover from financial difficulties[136]. Environmental Compliance - The company invested nearly 400 million yuan in environmental protection facilities to comply with national regulations and reduce wastewater discharge[57]. - The company has achieved compliance with pollutant discharge standards, with no major environmental issues reported during the reporting period[58]. - The company has implemented various pollution control systems, including advanced technologies for gas and wastewater treatment[59]. - The company has developed a self-monitoring plan for environmental compliance, with third-party assessments confirming that all discharge indicators meet standards[62]. Government Support and Financial Assistance - The company secured special relief funds from the local government to support its subsidiary, which has resumed production[35]. - The company signed a cooperation agreement for financial assistance with the local government to support its subsidiary, Zhongke New Materials[82]. - The company has successfully raised special relief funds through the Shizuishan Huinong District government financing platform to support Zhongke New Materials[68]. Shareholder Information - Total number of common shareholders as of the end of the reporting period is 33,308[86]. - The largest shareholder, Shanghai Zhongneng Enterprise Development (Group) Co., Ltd., holds 200,000,000 shares, accounting for 29.20% of total shares[87]. - The second-largest shareholder, Feng Liang, holds 27,392,229 shares, representing 4.00% of total shares[87]. Legal and Regulatory Matters - The company received a warning letter from the China Securities Regulatory Commission on June 1, 2023, due to regulatory violations, and has implemented corrective measures to enhance compliance awareness[72]. - The company is involved in significant litigation related to financial loan agreements, with Ningxia State-owned Assets Investment Holding Group filing a lawsuit against multiple parties including the company[70]. Financial Management and Accounting Policies - The company’s financial statements are prepared based on the principle of going concern, reflecting its financial position and operating results accurately[138]. - The company’s accounting policies are tailored to its operational characteristics, including revenue recognition and inventory measurement[137]. - The company includes all controlled subsidiaries in the consolidated financial statements, adjusting for any inconsistencies in accounting policies or periods[143]. Research and Development - Research and development expenses decreased by 64.96% to CNY 5.54 million, reflecting reduced investment from the subsidiary[38]. - The company has not reported any new product launches or technological advancements in the current period[127].

证券代码：600165 股票简称：宁科生物 公告编号：临 2023-045 宁夏中科生物科技股份有限公司 | 单位：万元 | | --- | 关于上海证券交易所对公司 2022 年年度报告 事后问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁夏中科生物科技股份有限公司（以下简称：公司）于2023年5月19日收到上海 证券交易所《关于宁夏中科生物科技股份有限公司2022年年度报告的事后审核问询函》 （上证公函【2023】0569号）（以下简称：《问询函》）（具体详见：临2023-027号 公告），于2023年6月17日披露了《关于上海证券交易所对公司2022年年度报告事后 问询函的部分回复公告》（具体详见：临2023-034号公告），现将《问询函》中未披 露的问题第4、5项回复如下。本次回复后，公司对上证公函【2023】0569号《问询函》 的所有问题全部予以回复并披露。 4.关于流动性风险。公司流动性负债规模从 10.8 亿元上升至 15.67 亿元，公司一 年内到期的非流动负债有 3.7 亿元，同比增长 ...

证券代码：600165 股票简称：宁科生物 公告编号：临 2023-025 宁夏中科生物科技股份有限公司 关于召开 2022 年度网上业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 17 日（星期三）10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 报 中 国 证 券 网 路 演 中 心 （ 网 址 ： http://roadshow.cnstock.com/） 会议召开方式：网络互动 1 http://roadshow.cnstock.com/） （三）会议召开方式：网络互动 三、参加人员 投资者可于 2023 年 5 月 15 日（星期一）17:00 前将相关问题通过电子邮 件的形式发送至公司邮箱：official@ningkeshengwu.com。公司将在信息披露允 许范围内，在 2022 年度网上业绩说明会对投资者普遍关注的问题进行回答。 宁夏中科生物科技股份有限公司（以下简称：公司）已于 2023 年 4 月 28 日发布公司 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥46,109,368.75, representing a decrease of 72.34% compared to the same period last year[3] - The net profit attributable to shareholders was -¥58,433,529.67, indicating a significant loss[3] - The company reported a basic and diluted earnings per share of -¥0.085[3] - The weighted average return on equity was -9.737%[3] - Total revenue for Q1 2023 was CNY 46,109,368.75, a decrease of 72.5% compared to CNY 166,716,293.63 in Q1 2022[16] - Net loss for Q1 2023 was CNY 66,686,256.61, compared to a net loss of CNY 27,903,539.27 in Q1 2022, representing a 139.2% increase in losses[17] - Basic and diluted earnings per share for Q1 2023 were both CNY -0.085, compared to CNY -0.034 in Q1 2022[18] - Total equity attributable to shareholders was CNY 571,150,551.54, down from CNY 629,309,835.41 in Q1 2022, a decrease of 9.2%[16] Cash Flow and Liquidity - The net cash flow from operating activities was -¥42,832,422.48, reflecting a decline in cash generation[3] - Operating cash flow for Q1 2023 was negative CNY 42,832,422.48, an improvement from negative CNY 87,572,135.13 in Q1 2022[18] - Cash inflow from operating activities was CNY 55,549,016.24 in Q1 2023, compared to CNY 162,513,832.34 in Q1 2022, a decline of 65.9%[18] - The company's cash and cash equivalents decreased to ¥35,779,145.22 from ¥89,483,876.89, representing a significant decline of approximately 60%[13] - The cash and cash equivalents at the end of the period were 9,415,253.24, down from 26,318,342.47 in the prior period[19] - The company reported a net decrease in cash and cash equivalents of -33,789,917.96, compared to -66,679,303.33 in the prior period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,216,319,042.22, down 1.90% from the previous year-end[4] - Total liabilities as of Q1 2023 were CNY 2,388,649,968.19, slightly up from CNY 2,384,616,750.65 in Q1 2022[16] - Shareholders' equity attributable to the company was ¥571,150,551.54, a decrease of 9.24% compared to the previous year-end[4] - The company's non-current assets totaled ¥3,007,334,369.72, down from ¥3,026,839,472.43, indicating a decrease of about 0.6%[14] Operational Challenges - The company is currently facing risks related to the temporary suspension of operations at its subsidiary, Zhongke New Materials, due to a breach of capital contribution agreement by Jinan Changyue, which has led to a halt in production[10] - The company is actively seeking financing solutions to address the operational challenges at Zhongke New Materials and aims to resume production within three months[11] - The company has disclosed that it will not pursue preferential subscription rights in the capital increase of its subsidiary, Zhongke New Materials, which may impact future capital structure and funding strategies[10] Changes in Expenses and Receivables - The company experienced a 90.33% increase in prepayments, primarily due to advance payments for technical services by its subsidiary[7] - The company’s sales expenses decreased by 43.55%, attributed to a decline in sales volume at its subsidiary[7] - Accounts receivable decreased to ¥27,483,532.85 from ¥32,676,410.20, a reduction of about 16%[13] - Inventory increased to ¥112,904,551.57 from ¥109,305,912.49, showing a slight increase of approximately 2.4%[14] Financing Activities - Cash inflow from financing activities totaled 188,400,000.00, an increase from 153,980,498.05 in the prior period[19] - The company received 134,600,000.00 in borrowings, up from 115,000,000.00 in the previous period[19] - The net cash flow from financing activities was 9,824,818.42, a decrease from 29,394,200.76 in the previous period[19]

Group 1: Event Details - The company will participate in the "2023 Ningxia Listed Companies Investor Collective Reception Day" [2] - The event will be held online on May 11, 2023, from 14:00 to 17:00 [2] - Investors can join via the "Panjing Roadshow" website, WeChat public account, or the Panjing Roadshow APP [2] Group 2: Company Representatives - The company's General Manager, CFO, and Board Secretary will be present to communicate with investors [2] - Topics of discussion will include the company's 2022 performance, governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [2] Group 3: Investor Engagement - The company encourages active participation from investors during the event [2] - The initiative aims to strengthen interaction and communication with investors [2]

Financial Performance - The company reported a net profit of -18,162,854.95 RMB for the year 2022, resulting in a cumulative profit available for distribution to shareholders of -206,709,117.34 RMB at the end of the year[5]. - The company will not implement any profit distribution or capital reserve transfer to increase share capital for the year 2022 due to the negative profit situation[5]. - The company's operating revenue for 2022 was approximately ¥681.13 million, representing a year-over-year increase of 173.86% compared to ¥248.72 million in 2021[22]. - The net loss attributable to shareholders for 2022 was approximately ¥141.48 million, an improvement from a loss of ¥166.09 million in 2021[22]. - The basic earnings per share for 2022 was -¥0.207, compared to -¥0.243 in 2021, indicating a reduction in losses[23]. - The total assets at the end of 2022 were approximately ¥3.28 billion, a slight decrease of 0.82% from ¥3.31 billion at the end of 2021[22]. - The cash flow from operating activities for 2022 was approximately ¥53.14 million, a significant improvement from a negative cash flow of ¥17.93 million in 2021[22]. - The weighted average return on equity for 2022 was -20.224%, compared to -19.023% in 2021, reflecting continued challenges in profitability[23]. - The company reported a quarterly operating revenue of ¥308.59 million in Q2 2022, the highest among the four quarters[25]. - The net profit attributable to shareholders in Q2 2022 was approximately ¥31.86 million, marking a significant recovery from losses in other quarters[25]. Audit and Compliance - The audit report issued by the accounting firm indicates a qualified opinion, highlighting the need for investors to review the detailed explanations provided in the report[4]. - The company’s financial statements have been audited by 信永中和会计师事务所, which is responsible for ensuring the accuracy and completeness of the financial reports[4]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures in providing guarantees to external parties[7]. - The company received a regulatory warning from the Shanghai Securities Regulatory Commission on August 22, 2022, involving its controlling shareholder and several executives[130]. - The company received a qualified audit opinion from Xinyong Zhonghe for its 2022 financial statements[169]. Business Operations and Strategy - The company has not disclosed any plans for market expansion, new product development, or mergers and acquisitions in the current report[6]. - The company is committed to enhancing its profitability by continuously expanding its market presence and developing new products in response to market demands[37]. - The company is currently developing several new technologies, including a new fermentation process for lauric acid and a coal-based activated carbon for acetone adsorption[62]. - The company aims to enhance its production capabilities in the lauric acid industry, focusing on high-end products and reducing reliance on imports[72]. - The company is exploring market expansion and new product development through strategic partnerships and technological innovations[73]. - The company is actively seeking financing solutions to address the temporary production halt at its subsidiary, with a goal to resume operations within three months[110]. Environmental and Sustainability Efforts - The company invested approximately 400 million yuan in environmental protection facilities during the reporting period[153]. - The company has established environmental protection mechanisms and complies with relevant laws and standards[152]. - The company has taken measures to reduce carbon emissions through technology development, improving production efficiency, and reducing raw material and energy consumption[161]. - The company has developed an emergency response plan for environmental incidents, which has been filed and includes regular training for employees[159]. - The company is listed as a key pollutant discharge unit by the Ningxia Environmental Protection Department[153]. Research and Development - The company has established innovation platforms, including the Ningxia Biobased Materials Engineering Research Center, to enhance its R&D capabilities[73]. - The company has a dedicated R&D team of 61 personnel, with 31 members under the age of 40, focusing on innovative production techniques[78]. - The company’s R&D expenses increased by 24.63% to 25.51 million yuan, reflecting ongoing innovation efforts[46]. - The company is focusing on the continuous R&D of bio-based long-chain dicarboxylic acid production technology, achieving significant improvements in product quality stability, efficiency, and cost reduction[73]. Governance and Management - The company adheres to legal and regulatory requirements in corporate governance, ensuring clear responsibilities among shareholders, board members, and management[113]. - The company has established a robust investor relations management system to facilitate communication with investors[115]. - The company has a comprehensive information disclosure policy to ensure all shareholders have equal access to information[115]. - The company has experienced a shift in its governance structure with the election of new independent directors[129]. - The company is committed to aligning its executive compensation with performance metrics as per its established remuneration system[127]. Market and Competitive Position - The long-chain dicarboxylic acid market is expected to grow continuously, driven by the demand for lightweight materials in the automotive and electronics industries during the 14th Five-Year Plan period[35]. - The activated carbon industry is anticipated to expand due to increasing environmental awareness and demand in sectors such as water treatment and air purification[36]. - The company plans to enhance its competitive edge by focusing on the independent research and development of lauric acid production technology and expanding its product offerings[105]. - The company is actively pursuing strategies for market expansion and product innovation to drive future growth[1]. Financial Position and Shareholder Relations - The company has implemented a cash dividend policy, prioritizing cash distribution to protect investors' rights, with a plan for shareholder returns from 2021 to 2023[143]. - The total remuneration for all directors, supervisors, and senior management was 3.8498 million yuan[127]. - The company has not engaged in any significant related party transactions that could affect its independence[116]. - The company reported a total revenue of 619,070 million in 2022, showing a significant increase compared to previous years[118]. - The company is committed to optimizing its asset structure and exploring diversified development to enhance its risk resistance and sustainable growth capabilities[105].

Financial Performance - The company's operating revenue for the first half of 2022 reached RMB 475.30 million, a significant increase of 462.75% compared to RMB 84.46 million in the same period last year[19]. - The net profit attributable to shareholders of the listed company was RMB 8.91 million, recovering from a loss of RMB 26.67 million in the previous year[19]. - The net cash flow from operating activities was RMB 9.68 million, a recovery from a negative cash flow of RMB 48.99 million in the same period last year[19]. - Basic earnings per share for the first half of 2022 were RMB 0.013, compared to a loss of RMB 0.039 per share in the same period last year[20]. - The total operating revenue for the first half of 2022 reached RMB 475.30 million, a significant increase from RMB 84.46 million in the same period of 2021, representing a growth of 462.5%[116]. - The net profit for the first half of 2022 was RMB 7.24 million, a turnaround from a net loss of RMB 30.67 million in the same period of 2021[117]. - The total comprehensive income for the first half of 2022 was RMB 7.48 million, compared to a loss of RMB 30.30 million in the same period of 2021[117]. Assets and Liabilities - The total assets of the company increased by 3.37% to RMB 3.41 billion compared to the end of the previous year[19]. - The total liabilities due within one year increased to ¥146,833,826.31, representing 4.30% of total assets, up 80.47% from the previous year[42]. - Total liabilities rose to ¥2,345,662,581.68, compared to ¥2,242,039,576.61, indicating an increase of about 4.63%[109]. - The company's total equity attributable to shareholders at the end of the reporting period was 684,883.78 million RMB, reflecting a decrease of 30,277.99 million RMB from the previous year[136]. - The total owner's equity at the end of the reporting period is 1,005,250,869.34, with a capital stock of 684,883,775.00 and retained earnings of -145,470,346.27[142]. Research and Development - The company’s research and development expenses increased by 545.65% to RMB 15.80 million, reflecting a strong commitment to innovation[38]. - The company aims to improve product quality continuously through ongoing technological research and development[29]. - The company plans to deepen cooperation with the Chinese Academy of Sciences to enhance its innovation capabilities in the long-chain dicarboxylic acid sector[36]. Environmental and Regulatory Compliance - The company has implemented various pollution control systems, including a biological fermentation tail gas treatment system and a comprehensive wastewater treatment system[71]. - The company has established an emergency response plan for environmental incidents and conducts regular training for employees[74]. - The company has obtained necessary environmental impact assessments and discharge permits for its projects[73]. - The company is listed as a key pollutant discharge unit in Ningxia, with three main discharge outlets[68]. Market and Business Strategy - The company employs a mixed sales model combining direct sales, distribution, and consignment to expand both domestic and international markets[30]. - The market demand for long-chain dicarboxylic acid is expected to continue growing, driven by the expansion of the long-chain nylon industry during the 14th Five-Year Plan period[29]. - The company has established a comprehensive procurement, production, sales, R&D, and customer service system to enhance profitability[31]. Investment and Acquisitions - The company completed the acquisition of an additional 49% stake in Zhongke New Materials, raising its ownership from 31% to 80%[47]. - The company plans to acquire an additional 10% stake in Zhongke New Materials, increasing its ownership to 90%[48]. - The company borrowed a total of RMB 500 million from Guangdong Hongjun Investment Co., Ltd. to repurchase a 49% stake in Hengli New Materials[88]. Risk Factors - The company has described potential risks in the "Management Discussion and Analysis" section of the report[4]. - Fluctuations in raw material prices, particularly for long-chain dicarboxylic acid and coal-based activated carbon, may impact gross margins; the company will adjust procurement strategies to mitigate these risks[55]. - Changes in government subsidy policies could affect operational performance; the company aims to strengthen R&D and production technology to improve profitability[55]. - The ongoing COVID-19 pandemic poses risks to logistics and supply chain management; the company will adhere to national prevention measures to minimize operational disruptions[56]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 23,345[96]. - The top shareholder, Shanghai Zhongneng Enterprise Development (Group) Co., Ltd., holds 200,000,000 shares, representing 29.20% of the total shares[98]. - The company has not reported any changes in the controlling shareholder or actual controller during the reporting period[100]. Financial Reporting and Compliance - The financial report for the first half of 2022 has not been audited[6]. - The company’s financial statements comply with the requirements of enterprise accounting standards, reflecting its financial status and operating results accurately[156]. - The company’s accounting period runs from January 1 to December 31 each year[157].

Financial Performance - The company's operating revenue for Q1 2022 was ¥166,716,293.63, representing a significant increase of 335.76% compared to the same period last year[3]. - The net profit attributable to shareholders was a loss of ¥22,955,758.38, a decrease of 928.87% year-over-year[3]. - The net cash flow from operating activities was negative at ¥87,572,135.13, reflecting a decline of 2,358.94% compared to the previous year[3]. - Basic and diluted earnings per share were both -¥0.0335, a decrease of 937.50% year-over-year[3]. - The net loss for Q1 2022 was ¥27.90 million, compared to a net profit of ¥0.56 million in Q1 2021, indicating a shift in financial performance[15][16]. - The company's gross profit margin for Q1 2022 was approximately -23.8%, down from a positive margin in the previous year[15]. - The company reported a total comprehensive loss of ¥27.71 million for Q1 2022, compared to a comprehensive income of ¥0.70 million in Q1 2021[16]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,290,453,763.98, down 5.04% from the previous year[3]. - Current assets totaled CNY 302,815,704.36, slightly up from CNY 302,056,104.92, indicating a marginal increase of about 0.25%[12]. - The company's long-term equity investments amounted to CNY 661,462,128.88, up from CNY 652,016,329.76, showing a growth of about 1.5%[12]. - Total liabilities as of Q1 2022 amounted to ¥2.27 billion, slightly up from ¥2.24 billion in the previous year[13]. - Total liabilities amounted to approximately 2.24 billion, with current liabilities at about 1.08 billion and non-current liabilities at approximately 1.16 billion[23]. Shareholders' Equity - Shareholders' equity attributable to the company decreased by 19.74% to ¥733,166,573.12 compared to the end of the previous year[3]. - The equity attributable to shareholders of the parent company decreased to ¥733.17 million in Q1 2022 from ¥913.44 million in Q1 2021[13]. - Shareholders' equity totaled approximately 1.22 billion, with equity attributable to the parent company at around 913.44 million[23]. Cash Flow - Cash inflow from operating activities in Q1 2022 was CNY 162,513,832.34, a significant increase from CNY 54,092,705.02 in Q1 2021, representing a growth of 200.5%[19]. - Net cash outflow from operating activities in Q1 2022 was CNY -87,572,135.13, compared to a positive cash flow of CNY 3,876,689.24 in Q1 2021[19]. - Cash inflow from financing activities in Q1 2022 totaled CNY 153,980,498.05, up from CNY 109,000,000.00 in Q1 2021, marking an increase of 41.2%[20]. - The ending cash and cash equivalents balance as of Q1 2022 was CNY 26,318,342.47, down from CNY 285,423,416.09 at the end of Q1 2021[20]. Research and Development - Research and development expenses increased by 781.01% due to higher investment in R&D activities by the subsidiary[5]. - Research and development expenses increased to ¥6.94 million in Q1 2022, compared to ¥0.79 million in Q1 2021, reflecting a focus on innovation[15]. Inventory and Receivables - The company reported a significant increase in inventory by 63.71% due to reclassification of trial production products[5]. - Accounts receivable increased to CNY 23,538,868.48 from CNY 19,526,701.88, marking an increase of about 20.5%[11]. - Inventory rose significantly to CNY 159,970,089.39 from CNY 97,714,459.00, reflecting an increase of approximately 63.6%[11]. Government Subsidies and Adjustments - The company received government subsidies amounting to ¥2,349,969.04 related to the elimination of outdated production capacity[4]. - The company made retrospective adjustments to revenue and costs related to the sale of products generated during the trial production of the month桂二酸 project[24]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,498[6]. - The company has no significant related party transactions among the top shareholders, ensuring independent operations[9]. - The company has not reported any significant new strategies or product developments during the quarter[10].